Bloomberg (Sept 26) US regulators are still scrutinizing Eli Lilly’s experimental blood-thinner prasugrel, delaying marketing of the drug (as Effient). While study results have shown that prasugrel prevents more heart attacks and strokes compared to Plavix (BMS and Sanofi-Aventis), more people on this experimental drug died from bleeding than those taking Plavix. click here